You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A Brown University-led team demonstrated the utility of its "massively parallel splicing assay," or MaPSy, assay by profiling splice effects for thousands of mutations.
Bioké will exclusively distribute Acea's xCelligence cell analyzer in Belgium, the Netherlands, and Luxembourg.
Privately held TransCell specializes in primary cell-based phenotypic screening assays.
The company plans to use the funds to support the worldwide launch of its commercial platform for propagation and gene editing in cell types that are difficult to transfect.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
Analysis of a gene associated with basal progenitor cell expansions in the brain suggests a single splice site change led to human-specific forms of the gene transcript.
Notable is adopting Labcyte's Echo acoustic liquid handling platform to screen cancer patients' tumor cells for response to individual and combination therapies.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
Cambridge Bioscience will exclusively distribute the Xcell platform in the UK and BioStream will disburse the system in Japan.
At AGBT, Fluidigm showcased the Polaris system for integrated single-cell analysis and new applications for the C1, including high-throughput RNA-seq and protein analysis.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.